Translational Research Institute - Innovate. Discover. Cure.
We love a good challenge. As it turns out, our partners do, too. When like-minded health care providers with different talents start taking on complex challenges together, the results can be astonishingly more beneficial for the patients we serve, and the partners with whom we form alliances.
For Florida Hospital’s new Translational Research Institute (TRI), a 54,000 square-foot facility devoted to the study of obesity and the metabolic origins of cardiovascular disease, strategic partnerships will aid in the development of new treatments to battle diabetes and obesity. The new facility (expected to be fully operational in early 2012) will house some of the most technologically advanced clinical and diagnostic equipment in the country, including state-of-the-art calorimetry chambers, a biorespository, 3T MRI scanner, DEXA scan, clinic space and testing rooms. Ensuring this facility performs well for our patients and our partners are Directors Steven Smith, MD, and Richard Pratley, MD. They will lead a highly specialized team to provide the necessary scientific and clinical expertise in administering patient-oriented research and appropriately tracking results.
Finding value in this world-class endeavor are current partners like Takeda Pharmaceutical Company Ltd., Japan’s largest pharmaceutical developer, and Sanford-Burnham Medical Research Institute, a top-ranked US research institute. Our combined talents align complementary strengths in biomedical research, clinical research and drug development; a collaboration which will dramatically reduce the distance between research and treatment, resulting in a quicker delivery of more personalized therapies.
This collaborative, multi-disciplinary team of doctors, scientists, and researchers of TRI and Sanford-Burnham will provide Takeda with a research continuum from laboratory bench to patient bedside. “TRI provides a virtual bridge between Florida Hospital and [Sanford-Burnham],” said Daniel Kelly, MD, Scientific Director at Sanford-Burnham. “Information will speed back and forth to accelerate discoveries leading to new treatments. It offers much promise for expediting new drug candidates into Takeda’s development pipeline.”
As the first corporate-sponsored research program jointly undertaken by Sanford-Burnham and TRI, this initiative could become the model for developing new treatments in cancer, neurosciences, infectious diseases and children’s health. For Takeda, this alliance represents one of the largest and most ambitious discovery research partnerships it has ever conducted with the not-for-profit sector. “We view this collaboration as an opportunity to further Takeda’s goal of identifying targets for new therapeutics to treat obesity and its negative health consequences, including metabolic syndrome, diabetes and heart disease,” commented Dr. Paul Chapman, General Manager and Head of Pharmaceutical Research Division of Takeda.
By bringing unique capabilities like this to a health hub like Central Florida, it’s no surprise that companies like Takeda and Sanford-Burnham prefer to partner with Florida Hospital. Their affiliation with our efforts will only strengthen the validity of the combined research findings due to our high clinical standards and valued reputation within the health care industry. It is because of this that our existing partners can be confident this research will translate into tangible, real-world treatments and that equally significant medical breakthroughs will be possible through new partnerships yet to be established.
Learn more about the Translational Research Institute (TRI)